Austerity in Portugal drops drug bill 21%, drives parallel exports, hospital debt
This article was originally published in Scrip
Executive Summary
Market conditions in Portugal are continuing to deteriorate as cost cutting has fuelled parallel exports and hospitals owe companies increasingly more money, APIFARMA, the local R&D-based pharmaceutical industry association, has warned.
You may also be interested in...
Portugal: An Uptick In Life Science VC Funding
An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.